

L10 0 SEA SSS FUL L9

=>
Uploading rkc518h.str

L11 STRUCTURE UPLOADED

=> s l11
SAMPLE SEARCH INITIATED 13:35:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 0 TO 0

L12 0 SEA SSS SAM L11

=> s l11 ful
FULL SEARCH INITIATED 13:36:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 123 TO ITERATE


100.0% PROCESSED 123 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L13 2 SEA SSS FUL L11

=> d 1-2

L13 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 379260-16-9 REGISTRY
CN Carbamic acid, [imino[4-[[[2-[[[1S]-1-(4-methylphenyl)ethyl]amino]-2-oxoethyl]amino]carbonyl]amino]phenyl]methyl]-, 4-methoxyphenyl ester (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C27 H29 N5 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 159216-57-6 REGISTRY
CN Glycine, N-[N-[N-[[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]phenyl]amino]carbonyl]glycyl]-L-.alpha.-aspartyl]-L-2-phenyl-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H48 N6 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

Uploading rkc518f.str

L14 STRUCTURE UPLOADED

=> s l14 ful

FULL SEARCH INITIATED 13:37:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 123 TO ITERATE

100.0% PROCESSED 123 ITERATIONS
SEARCH TIME: 00.00.01

45 ANSWERS

L15 45 SEA SSS FUL L14

=>


Uploading rkc518b.str

L16 STRUCTURE UPLOADED

=> d

L16 HAS NO ANSWERS

L16 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l16 ful

FULL SEARCH INITIATED 13:38:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 123 TO ITERATE

100.0% PROCESSED 123 ITERATIONS
SEARCH TIME: 00.00.01

45 ANSWERS

L17 45 SEA SSS FUL L16

=>


Uploading rkc518c.str

L18 STRUCTURE UPLOADED

=> d

L18 HAS NO ANSWERS

L18 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l18 ful

FULL SEARCH INITIATED 13:40:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 123 TO ITERATE

100.0% PROCESSED 123 ITERATIONS
SEARCH TIME: 00.00.01

95 ANSWERS

L19 95 SEA SSS FUL L18

=>

Uploading rkc518e.str

L20 STRUCTURE UPLOADED

=> d

L20 HAS NO ANSWERS

L20 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l20 ful

FULL SEARCH INITIATED 13:41:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 123 TO ITERATE

100.0% PROCESSED 123 ITERATIONS
SEARCH TIME: 00.00.01

4 ANSWERS

L21 4 SEA SSS FUL L20

=> d 1-4

L21 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN

RN 379259-92-4 REGISTRY

CN Acetamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[(1S)-1-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C18 H20 N6 O4

SR CA

LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L21 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 379259-74-2 REGISTRY
CN Acetamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[(4-aminophenyl)methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H20 N6 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L21 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 379259-66-2 REGISTRY
CN Acetamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl)methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H24 N6 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L21 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 379259-63-9 REGISTRY
CN Benzenepropanamide, .alpha.-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl)methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H30 N6 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1577.42	1577.63

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:41:41 ON 06 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jan 2004 VOL 140 ISS 2
FILE LAST UPDATED: 5 Jan 2004 (20040105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l19
L22

4 L19

=> d fbib abs fhitr

L22 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:262954 CAPLUS
DN 139:173167
TI Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors
AU Klingler, Otmar; Matter, Hans; Schudok, Manfred; Bajaj, S. Paul; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Schreuder, Herman; Wildgoose, Peter
CS Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(8), 1463-1467
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English

AB Selective inhibition of coagulation factor VIIa has recently gained attraction as interesting approach towards antithrombotic treatment. Using parallel synthesis supported by structure-based design and x-ray crystallog., we were able to identify a novel series of amidinophenylurea derivs. with remarkable affinity for factor VIIa. The most potent compd. displays a Ki value of 23 nM for factor VIIa.


IT 379259-63-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors)

RN 379259-63-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 1-4 fbib abs fhitr

L22 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:262954 CAPLUS

DN 139:173167

TI Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors

AU Klingler, Otmar; Matter, Hans; Schudok, Manfred; Bajaj, S. Paul; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Schreuder, Herman; Wildgoose, Peter

CS Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany

SO Bioorganic & Medicinal Chemistry Letters (2003), 13(8), 1463-1467

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English

AB Selective inhibition of coagulation factor VIIa has recently gained attraction as interesting approach towards antithrombotic treatment. Using parallel synthesis supported by structure-based design and x-ray crystallog., we were able to identify a novel series of amidinophenylurea derivs. with remarkable affinity for factor VIIa. The most potent compd. displays a Ki value of 23 nM for factor VIIa.


IT 379259-63-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors)

RN 379259-63-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl] amino]-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:900125 CAPLUS
DN 136:19952
TI Preparation of carbamimidoylphenylurea derivatives and thio analogs as
factor VIIa inhibitors
IN Klingler, Otmar; Schudok, Manfred; Nestler, Hans-Peter; Matter, Hans;
Schreuder, Herman
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1162194	A1	20011212	EP 2000-112116	20000606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001094301	A2	20011213	WO 2001-EP6029	20010526
WO 2001094301	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1299354	A2	20030409	EP 2000-112116 A	20000606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011264	A	20030617	EP 2000-112116 A	20000606
WO 2001-EP6029 W 20010526				
BR 2001-11264 20010526				
EP 2000-112116 A 20000606				
WO 2001-EP6029 W 20010526				
JP 2003535844	T2	20031202	JP 2002-501818	20010526
EP 2000-112116 A 20000606				
WO 2001-EP6029 W 20010526				
US 2002052417	A1	20020502	US 2001-874318	20010606
EP 2000-112116 A 20000606				
NO 2002005810	A	20021203	NO 2002-5810	20021203
EP 2000-112116 A 20000606				
WO 2001-EP6029 W 20010526				

OS MARPAT 136:19952
GI



I



II

AB Carbamimidoylphenyl urea derivs. I (X = O; R1 = H, OH, alkoxy, carbonyl, (un)substituted arylalkoxy, carbonyl and aryloxy, carbonyl; R2 = H, alkyl, aryl, arylalkyl, (un)substituted arylalkyl and alkylaryl; R3 = H, CN, OH, alkyl; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; R5 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, arylalkylaminocarbonyl, heterocyclealkylaminocarbonyl; R4 and R5 may together with the carbon atom to which they are attached form a (un)substituted 3-8 membered ring which is carbocyclic or heterocyclic; R6 = H, OH, alkoxy, arylalkoxy; A = halogen; m = 0-4; n = 0-3) and their thiourea analogs I (X = S) are prepd. and their use as factor VIIa inhibitors is disclosed. Thus, compd. II was prepd. by amidation of L-alanine Et ester with 4-aminobenzonitrile with subsequent hydrolysis, amidation, addn. of hydrogen sulfide, methylation and reaction with ammonia. I exhibited strong antithrombotic effects and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. Inhibition const. of I towards factor VIIa/tissue factor ranged from 0.13-20.2 uM. I are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended.

IT 379259-62-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restenoses)

RN 379259-62-8 CAPLUS

CN Propanamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(aminoiminomethyl)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:397079 CAPLUS
DN 122:161379
TI Preparation of amidinophenylureidoalkylamide peptide analogs useful as
platelet aggregation inhibitors.
IN Tjoeng, Foe S.; Toth, Mihaly V.; McMackins, Dudley E.; Adams, Steven P.
PA Monsanto Co., USA
SO U.S., 21 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5314902	A	19940524	US 1993-9526	19930127
	WO 9417041	A1	19940804	WO 1994-US511	19940124
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9460286	A1	19940815	US 1993-9526	19930127
				AU 1994-60286	19940124
				US 1993-9526	19930127
				WO 1994-US511	19940124
	US 5475025	A	19951212	US 1994-202148	19940223
				US 1993-9526	19930127
	US 5624956	A	19970429	US 1995-449446	19950524
				US 1993-9526	19930127
				US 1994-202148	19940223
OS	MARPAT 122:161379				
GI					




AB Title compds. [I; R, R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, alicyclyl, aryl, heterocyclyl; W = H, alkyl, alkenyl, alkynyl, alicyclyl, aryl; Z, Z1 = H, alkyl, halo, alkoxy, cyano, sulfonyl, OH; X = O, S, imino; m = 0-6; n = 0-3], were prepd. Thus, 4-NCC6H4NCO was stirred with H2NCH2CH2CO2H and NaOH in MeOH/EtOAc to give 4-NCC6H4NHCONHCH2CH2CO2H. This was stirred 2 h with disuccinimidyl carbonate, 4-dimethylaminopyridine, and HCl in DMF/dioxane; H2NCH(X)CH2CO2Et.2HCl (X = 3-pyridyl) and diisopropylethylamine in DMF were added and the mixt. was stirred overnight to give 4-NCC6H4NHCONHCH2CH2CONHCH(X)CO2Et, which was subsequently converted to title compd. (II). II inhibited collagen-induced platelet aggregation in beagle platelet rich plasma with IC50 = 3.3 .times. 10-7 M.

IT 161354-89-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as blood platelet aggregation inhibitor)

RN 161354-89-8 CAPLUS




CN .beta.-Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]glycyl]-3-(3-pyridinyl)-, ethyl ester, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

AN 1994:701334 CAPLUS
 DN 121:301334
 TI Preparation of ureidopeptides as inhibitors of thrombocyte aggregation, cancer cell metastasis, and osteoclast binding to bone surfaces.
 IN Klingler, Otmar; Just, Melitta; Breipohl, Gerhard; Koenig, Wolfgang; Jablonka, Bernd; Zoller, Gerhard; Knolle, Jochen; Stilz, Hans Ulrich
 PA Cassella AG, Germany
 SO Ger. Offen., 16 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4309867	A1	19940929	DE 1993-4309867	19930326
	CA 2155843	AA	19941013	CA 1994-2155843	19940309
	WO 9422907	A1	19941013	DE 1993-4309867A	19930326
	W: AU, CA, HU, JP, KR, US			WO 1994-EP713	19940309
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			DE 1993-4309867A	19930326
	AU 9463754	A1	19941024	AU 1994-63754	19940309
	AU 679509	B2	19970703	DE 1993-4309867A	19930326
				WO 1994-EP713 W	19940309
	EP 689549	A1	19960103	EP 1994-911129	19940309
	EP 689549	B1	19980617		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			DE 1993-4309867A	19930326
	HU 73409	A2	19960729	WO 1994-EP713 W	19940309
	HU 219483	B	20010428	HU 1995-2792	19940309
				DE 1993-4309867A	19930326
	JP 08508267	T2	19960903	JP 1994-521591	19940309
				DE 1993-4309867A	19930326
				WO 1994-EP713 W	19940309
	AT 167483	E	19980715	AT 1994-911129	19940309
				DE 1993-4309867A	19930326
	ES 2119187	T3	19981001	ES 1994-911129	19940309
				DE 1993-4309867A	19930326
	ZA 9402124	A	19941110	ZA 1994-2124	19940325
				DE 1993-4309867A	19930326
	IL 109135	A1	19990312	IL 1994-109135	19940325
				DE 1993-4309867A	19930326
	US 5703050	A	19971230	US 1996-513815	19960117
				DE 1993-4309867A	19930326
				WO 1994-EP713 W	19940309
OS	MARPAT 121:301334				
GI					




AB R1AC(:Z)BNRCR2R3(CH2)rW [r = 0-3; Z = O, S; W = COW1, tetrazolyl, SO3H, SO2NHR9; W1 = OH, alkoxy, amino, (substituted) arylalkoxy, aryloxy; A = (CH2)kNRa, Q1; n, p = 0-4; k = 1-4; B = NRb(CH2)mCO, NRbCHRsCO, Q2, Q3; s, t = 0-5; Rs = amino acid side chain; Ra, Rb = H, OH, alkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, (substituted) aryl, arylalkyl, aryloxy, arylalkoxy, etc.; R = H, alkyl; R1 = NHX, C(:NX)NH2; X = H, cyano, OH, alkoxy, amino, alkyl, alkylcarbonyl, alkoxycarbonyl, (substituted) arylcarbonyl, aryloxycarbonyl, etc.; R2 = H, (substituted) alkyl, Ph; R3 = H, CO2R4, CONMeR4, CONHR4; R4 = H, (substituted) alkyl; R9 = H, aminocarbonyl, alkyl, cycloalkyl], were prepd. as inhibitors of thrombocyte aggregation, cancer cell metastasis, and osteoclast formation (no data). Thus, [3-[4-(aminoiminomethyl)phenyl]ureido]acetylaspartylphenylglycine was prepd. via coupling of [3-[4-(tert-butyloxycarbonylaminoiminomethyl)phenyl]ureido]acetic acid Na salt (prepd. in several steps starting from Et isocyanatoacetate and 4-aminobenzonitrile) with H-Asp(OtBu)-Phg-OtBu (Phg = phenylglycyl) using DCC, hydroxybenzotriazole, and ethylmorpholine in DMF at 0.degree..

IT 159216-52-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of ureidopeptides as inhibitors of thrombocyte aggregation, cancer cell metastasis, and osteoclast binding to bone surfaces)

RN 159216-52-1 CAPLUS

CN Glycine, N-[N-[N-[[4-(aminoiminomethyl)phenyl]amino]carbonyl]glycyl]-L-.alpha.-aspartyl]-L-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s l13

L23 2 L13

=> d 1-2 fbib abs fhitr

L23 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:900125 CAPLUS

DN 136:19952

TI Preparation of carbamimidoylphenylurea derivatives and thio analogs as factor VIIa inhibitors

IN Klingler, Otmar; Schudok, Manfred; Nestler, Hans-Peter; Matter, Hans; Schreuder, Herman

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1162194	A1	20011212	EP 2000-112116	20000606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001094301	A2	20011213	WO 2001-EP6029	20010526
	WO 2001094301	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1299354	A2	20030409	EP 2000-112116 A	20000606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			EP 2001-955291	20010526
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
BR	2001011264	A	20030617	BR 2001-11264	20010526
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
JP	2003535844	T2	20031202	JP 2002-501818	20010526
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
US	2002052417	A1	20020502	US 2001-874318	20010606
				EP 2000-112116 A	20000606
NO	2002005810	A	20021203	NO 2002-5810	20021203
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526

OS MARPAT 136:19952
GI



I



II

AB Carbamimidoylphenyl urea derivs. I (X = O; R1 = H, OH, alkoxy-carbonyl, (un)substituted arylalkoxycarbonyl and aryloxycarbonyl; R2 = H, alkyl,

aryl, arylalkyl, (un)substituted arylalkyl and alkylaryl; R3 = H, CN, OH, alkyl; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; R5 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, arylalkylaminocarbonyl, heterocyclealkylaminocarbonyl; R4 and R5 may together with the carbon atom to which they are attached form a (un)substituted 3-8 membered ring which is carbocyclic or heterocyclic; R6 = H, OH, alkoxy, arylalkoxy; A = halogen; m = 0-4; n = 0-3) and their thiourea analogs I (X = S) are prepd. and their use as factor VIIa inhibitors is disclosed. Thus, compd. II was prepd. by amidation of L-alanine Et ester with 4-aminobenzonitrile with subsequent hydrolysis, amidation, addn. of hydrogen sulfide, methylation and reaction with ammonia. I exhibited strong antithrombotic effects and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. Inhibition consts. of I towards factor VIIa/tissue factor ranged from 0.13-20.2 uM. I are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended.

IT 379260-16-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restenoses)

RN 379260-16-9 CAPLUS

CN Carbamic acid, [imino[4-[[[2-[[[(1S)-1-(4-methylphenyl)ethyl]amino]-2-oxoethyl]amino]carbonyl]amino]phenyl]methyl]-, 4-methoxyphenyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:701334 CAPLUS

DN 121:301334

TI Preparation of ureidopeptides as inhibitors of thrombocyte aggregation, cancer cell metastasis, and osteoclast binding to bone surfaces.

IN Klingler, Otmar; Just, Melitta; Breipohl, Gerhard; Koenig, Wolfgang; Jablonka, Bernd; Zoller, Gerhard; Knolle, Jochen; Stilz, Hans Ulrich

PA Cassella AG, Germany

SO Ger. Offen., 16 pp.



CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4309867	A1	19940929	DE 1993-4309867	19930326
	CA 2155843	AA	19941013	CA 1994-2155843	19940309
	WO 9422907	A1	19941013	DE 1993-4309867A	19930326
	W: AU, CA, HU, JP, KR, US			WO 1994-EP713	19940309
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			DE 1993-4309867A	19930326
	AU 9463754	A1	19941024	AU 1994-63754	19940309
	AU 679509	B2	19970703		
				DE 1993-4309867A	19930326
				WO 1994-EP713 W	19940309
	EP 689549	A1	19960103	EP 1994-911129	19940309
	EP 689549	B1	19980617		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			DE 1993-4309867A	19930326
				WO 1994-EP713 W	19940309
	HU 73409	A2	19960729	HU 1995-2792	19940309
	HU 219483	B	20010428		
				DE 1993-4309867A	19930326
	JP 08508267	T2	19960903	JP 1994-521591	19940309
				DE 1993-4309867A	19930326
				WO 1994-EP713 W	19940309
	AT 167483	E	19980715	AT 1994-911129	19940309
				DE 1993-4309867A	19930326
	ES 2119187	T3	19981001	ES 1994-911129	19940309
				DE 1993-4309867A	19930326
	ZA 9402124	A	19941110	ZA 1994-2124	19940325
				DE 1993-4309867A	19930326
	IL 109135	A1	19990312	IL 1994-109135	19940325
				DE 1993-4309867A	19930326
	US 5703050	A	19971230	US 1996-513815	19960117
				DE 1993-4309867A	19930326
				WO 1994-EP713 W	19940309
OS	MARPAT 121:301334				
GI					



AB R1AC(:Z)BNRCR2R3(CH2)rW {r = 0-3; Z = O, S; W = COW1, tetrazolyl, SO3H, SO2NHR9; W1 = OH, alkoxy, amino, (substituted) arylalkoxy, aryloxy; A = (CH2)kNRa, Q1; n, p = 0-4; k = 1-4; B = NRb(CH2)mCO, NRbCHRsCO, Q2, Q3; s, t = 0-5; Rs = amino acid side chain; Ra, Rb = H, OH, alkyl, hydroxycarbonylalkyl, alkoxy carbonylalkyl, (substituted) aryl, arylalkyl, aryloxy, arylalkoxy, etc.; R = H, alkyl; R1 = NHX, C(:NX)NH2; X = H, cyano, OH, alkoxy, amino, alkyl, alkylcarbonyl, alkoxy carbonyl, (substituted) arylcarbonyl, aryloxy carbonyl, etc.; R2 = H, (substituted) alkyl, Ph; R3 = H, CO2R4, CONMeR4, CONHR4; R4 = H, (substituted) alkyl; R9 = H, aminocarbonyl, alkyl, cycloalkyl], were prepd. as inhibitors of

thrombocyte aggregation, cancer cell metastasis, and osteoclast formation (no data). Thus, [3-[4-(aminoiminomethyl)phenyl]ureido]acetylasparylphenylglycine was prepd. via coupling of [3-[4-(tert-butyloxycarbonylaminoiminomethyl)phenyl]ureido]acetic acid Na salt (prepd. in several steps starting from Et isocyanatoacetate and 4-aminobenzonitrile) with H-Asp(OtBu)-Phg-OtBu (Phg = phenylglycyl) using DCC, hydroxybenzotriazole, and ethylmorpholine in DMF at 0.degree..

IT 159216-57-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of ureidopeptides as inhibitors of thrombocyte aggregation, cancer cell metastasis, and osteoclast binding to bone surfaces)

RN 159216-57-6 CAPLUS

CN Glycine, N-[N-[N-[[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]phenyl]amino]carbonyl]glycyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s 115

L24 3 L15

=> d 1-3 fbib abs fhitr

L24 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:262954 CAPLUS

DN 139:173167

TI Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors

AU Klingler, Otmar; Matter, Hans; Schudok, Manfred; Bajaj, S. Paul; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Schreuder, Herman; Wildgoose, Peter

CS Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany

SO Bioorganic & Medicinal Chemistry Letters (2003), 13(8), 1463-1467

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English

AB Selective inhibition of coagulation factor VIIa has recently gained attraction as interesting approach towards antithrombotic treatment. Using parallel synthesis supported by structure-based design and x-ray crystallog., we were able to identify a novel series of amidinophenylurea derivs. with remarkable affinity for factor VIIa. The most potent compd. displays a Ki value of 23 nM for factor VIIa.

IT 379259-63-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors)

RN 379259-63-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:900125 CAPLUS

DN 136:19952

TI Preparation of carbamimidoylphenylurea derivatives and thio analogs as factor VIIa inhibitors

IN Klingler, Otmar; Schudok, Manfred; Nestler, Hans-Peter; Matter, Hans; Schreuder, Herman

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1162194	A1	20011212	EP 2000-112116	20000606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001094301	A2	20011213	WO 2001-EP6029	20010526
	WO 2001094301	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				EP 2000-112116 A	20000606
	EP 1299354	A2	20030409	EP 2001-955291	20010526
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
BR	2001011264	A	20030617	BR 2001-11264	20010526
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
JP	2003535844	T2	20031202	JP 2002-501818	20010526
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
US	2002052417	A1	20020502	US 2001-874318	20010606


NO 2002005810 A 20021203

EP 2000-112116 A 20000606
NO 2002-5810 20021203
EP 2000-112116 A 20000606
WO 2001-EP6029 W 20010526

OS MARPAT 136:19952
GI



I



II

AB Carbamimidoylphenyl urea derivs. I (X = O; R1 = H, OH, alkoxy, carbonyl, (un)substituted arylalkoxycarbonyl and aryloxycarbonyl; R2 = H, alkyl, aryl, arylalkyl, (un)substituted arylalkyl and alkylaryl; R3 = H, CN, OH, alkyl; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; R5 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, arylalkylaminocarbonyl, heterocyclealkylaminocarbonyl; R4 and R5 may together with the carbon atom to which they are attached form a (un)substituted 3-8 membered ring which is carbocyclic or heterocyclic; R6 = H, OH, alkoxy, arylalkoxy; A = halogen; m = 0-4; n = 0-3) and their thiourea analogs I (X = S) are prepd. and their use as factor VIIa inhibitors is disclosed. Thus, compd. II was prepd. by amidation of L-alanine Et ester with 4-aminobenzonitrile with subsequent hydrolysis, amidation, addn. of hydrogen sulfide, methylation and reaction with ammonia. I exhibited strong antithrombotic effects and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. Inhibition const. of I towards factor VIIa/tissue factor ranged from 0.13-20.2 uM. I are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended.

IT 379259-62-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restenoses)

RN 379259-62-8 CAPLUS

CN Propanamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(aminoiminomethyl)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:397079 CAPLUS
DN 122:161379
TI Preparation of amidinophenylureidoalkylamide peptide analogs useful as
platelet aggregation inhibitors.
IN Tjoeng, Foe S.; Toth, Mihaly V.; McMackins, Dudley E.; Adams, Steven P.
PA Monsanto Co., USA
SO U.S., 21 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5314902	A	19940524	US 1993-9526	19930127
	WO 9417041	A1	19940804	WO 1994-US511	19940124
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9460286	A1	19940815	US 1993-9526	19930127
				AU 1994-60286	19940124
				US 1993-9526	19930127
				WO 1994-US511	19940124
	US 5475025	A	19951212	US 1994-202148	19940223
				US 1993-9526	19930127
	US 5624956	A	19970429	US 1995-449446	19950524
				US 1993-9526	19930127
				US 1994-202148	19940223
OS	MARPAT 122:161379				
GI					




AB Title compds. [I; R, R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, alicyclyl, aryl, heterocyclyl; W = H, alkyl, alkenyl, alkynyl, alicyclyl, aryl; Z, Z1 = H, alkyl, halo, alkoxy, cyano, sulfonyl, OH; X = O, S, imino; m = 0-6; n = 0-3], were prepd. Thus, 4-NCC6H4NCO was stirred with H2NCH2CH2CO2H and NaOH in MeOH/EtOAc to give 4-NCC6H4NHCONHCH2CH2CO2H. This was stirred 2 h with disuccinimidyl carbonate, 4-dimethylaminopyridine, and HCl in DMF/dioxane; H2NCH(X)CH2CO2Et.2HCl (X = 3-pyridyl) and diisopropylethylamine in DMF were added and the mixt. was stirred overnight to give 4-NCC6H4NHCONHCH2CH2CONHCH(X)CO2Et, which was subsequently converted to title compd. (II). II inhibited collagen-induced platelet aggregation in beagle platelet rich plasma with IC50 = 3.3 .times. 10⁻⁷ M.

IT 161355-58-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as blood platelet aggregation inhibitor)

RN 161355-58-4 CAPLUS

CN .beta.-Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]glycyl]-3-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




=> s l17

L25

3 L17

=> d 1-3 fbib abs fhitstr

L25 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:262954 CAPLUS
 DN 139:173167
 TI Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors
 AU Klingler, Otmar; Matter, Hans; Schudok, Manfred; Bajaj, S. Paul; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Schreuder, Herman; Wildgoose, Peter
 CS Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(8), 1463-1467
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB Selective inhibition of coagulation factor VIIa has recently gained attraction as interesting approach towards antithrombotic treatment. Using parallel synthesis supported by structure-based design and x-ray crystallog., we were able to identify a novel series of amidinophenylurea derivs. with remarkable affinity for factor VIIa. The most potent compd. displays a Ki value of 23 nM for factor VIIa.
 IT 379259-63-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors)
 RN 379259-63-9 CAPLUS
 CN Benzenepropanamide, .alpha.-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:900125 CAPLUS
 DN 136:19952
 TI Preparation of carbamimidoylphenylurea derivatives and thio analogs as factor VIIa inhibitors
 IN Klingler, Otmar; Schudok, Manfred; Nestler, Hans-Peter; Matter, Hans; Schreuder, Herman
 PA Aventis Pharma Deutschland G.m.b.H., Germany
 SO Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1162194	A1	20011212	EP 2000-112116	20000606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

WO 2001094301 A2 20011213 WO 2001-EP6029 20010526
 WO 2001094301 A3 20020404
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1299354 A2 20030409 EP 2000-112116 A 20000606
 EP 2001-955291 20010526
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 EP 2000-112116 A 20000606
 WO 2001-EP6029 W 20010526
 BR 2001011264 A 20030617 BR 2001-11264 20010526
 EP 2000-112116 A 20000606
 WO 2001-EP6029 W 20010526
 JP 2003535844 T2 20031202 JP 2002-501818 20010526
 EP 2000-112116 A 20000606
 WO 2001-EP6029 W 20010526
 US 2002052417 A1 20020502 US 2001-874318 20010606
 EP 2000-112116 A 20000606
 NO 2002005810 A 20021203 NO 2002-5810 20021203
 EP 2000-112116 A 20000606
 WO 2001-EP6029 W 20010526

OS MARPAT 136:19952
 GI



I



II

AB Carbamimidoylphenyl urea derivs. I (X = O; R1 = H, OH, alkoxycarbonyl, (un)substituted arylalkoxycarbonyl and aryloxycarbonyl; R2 = H, alkyl, aryl, arylalkyl, (un)substituted arylalkyl and alkylaryl; R3 = H, CN, OH, alkyl; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; R5 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, arylalkylaminocarbonyl, heterocyclealkylaminocarbonyl; R4 and R5 may together with the carbon atom to which they are attached form a (un)substituted 3-8 membered ring which

is carbocyclic or heterocyclic; R6 = H, OH, alkoxy, arylalkoxy; A = halogen; m = 0-4; n = 0-3) and their thiourea analogs I (X = S) are prepd. and their use as factor VIIa inhibitors is disclosed. Thus, compd. II was prepd. by amidation of L-alanine Et ester with 4-aminobenzonitrile with subsequent hydrolysis, amidation, addn. of hydrogen sulfide, methylation and reaction with ammonia. I exhibited strong antithrombotic effects and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. Inhibition const. of I towards factor VIIa/tissue factor ranged from 0.13-20.2 uM. I are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended.

IT 379259-62-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restenoses)

RN 379259-62-8 CAPLUS

CN Propanamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(aminoiminomethyl)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:397079 CAPLUS

DN 122:161379

TI Preparation of amidinophenylureidoalkylamide peptide analogs useful as platelet aggregation inhibitors.

IN Tjoeng, Foe S.; Toth, Mihaly V.; McMackins, Dudley E.; Adams, Steven P.

PA Monsanto Co., USA

SO U.S., 21 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5314902	A	19940524	US 1993-9526	19930127
	WO 9417041	A1	19940804	WO 1994-US511	19940124
	W:		AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN		
	RW:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
				US 1993-9526	19930127
	AU 9460286	A1	19940815	AU 1994-60286	19940124

US 5475025 A 19951212


US 5624956 A 19970429

OS MARPAT 122:161379
GI

US 1993-9526 19930127
WO 1994-US511 19940124
US 1994-202148 19940223
US 1993-9526 19930127
US 1995-449446 19950524
US 1993-9526 19930127
US 1994-202148 19940223



I



II


AB Title compds. [I; R, R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, alicyclyl, aryl, heterocyclyl; W = H, alkyl, alkenyl, alkynyl, alicyclyl, aryl; Z, Z1 = H, alkyl, halo, alkoxy, cyano, sulfonyl, OH; X = O, S, imino; m = 0-6; n = 0-3], were prepd. Thus, 4-NCC6H4NCO was stirred with H2NCH2CH2CO2H and NaOH in MeOH/EtOAc to give 4-NCC6H4NHCONHCH2CH2CO2H. This was stirred 2 h with disuccinimidyl carbonate, 4-dimethylaminopyridine, and HCl in DMF/dioxane; H2NCH(X)CH2CO2Et.2HCl (X = 3-pyridyl) and diisopropylethylamine in DMF were added and the mixt. was stirred overnight to give 4-NCC6H4NHCONHCH2CH2CONHCH(X)CO2Et, which was subsequently converted to title compd. (II). II inhibited collagen-induced platelet aggregation in beagle platelet rich plasma with IC50 = 3.3 .times. 10⁻⁷ M.

IT 161355-58-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as blood platelet aggregation inhibitor)

RN 161355-58-4 CAPLUS

CN .beta.-Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]glycyl]-3-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



=> s 121

L26 2 L21

=> d 1-2 fbib abs fhitr

L26 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:262954 CAPLUS

DN 139:173167

TI Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors

AU Klingler, Otmar; Matter, Hans; Schudok, Manfred; Bajaj, S. Paul; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Schreuder, Herman; Wildgoose, Peter

CS Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany

SO Bioorganic & Medicinal Chemistry Letters (2003), 13(8), 1463-1467
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English

AB Selective inhibition of coagulation factor VIIa has recently gained attraction as interesting approach towards antithrombotic treatment. Using parallel synthesis supported by structure-based design and x-ray crystallog., we were able to identify a novel series of amidinophenylurea derivs. with remarkable affinity for factor VIIa. The most potent compd. displays a Ki value of 23 nM for factor VIIa.


IT 379259-63-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors)


RN 379259-63-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:900125 CAPLUS
 DN 136:19952
 TI Preparation of carbamimidoylphenylurea derivatives and thio analogs as
 factor VIIa inhibitors
 IN Klingler, Otmar; Schudok, Manfred; Nestler, Hans-Peter; Matter, Hans;
 Schreuder, Herman
 PA Aventis Pharma Deutschland G.m.b.H., Germany
 SO Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1162194	A1	20011212	EP 2000-112116	20000606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001094301	A2	20011213	WO 2001-EP6029	20010526
	WO 2001094301	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				EP 2000-112116 A	20000606
	EP 1299354	A2	20030409	EP 2001-955291	20010526
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
BR	2001011264	A	20030617	BR 2001-11264	20010526
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
JP	2003535844	T2	20031202	JP 2002-501818	20010526
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
US	2002052417	A1	20020502	US 2001-874318	20010606
				EP 2000-112116 A	20000606
NO	2002005810	A	20021203	NO 2002-5810	20021203
				EP 2000-112116 A	20000606
				WO 2001-EP6029 W	20010526
OS	MARPAT 136:19952				
GI					



I



II

AB Carbamimidoylphenyl urea derivs. I (X = O; R1 = H, OH, alkoxycarbonyl, (un)substituted arylalkoxycarbonyl and aryloxycarbonyl; R2 = H, alkyl, aryl, arylalkyl, (un)substituted arylalkyl and alkylaryl; R3 = H, CN, OH, alkyl; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; R5 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, arylalkylaminocarbonyl, heterocyclealkylaminocarbonyl; R4 and R5 may together with the carbon atom to which they are attached form a (un)substituted 3-8 membered ring which is carbocyclic or heterocyclic; R6 = H, OH, alkoxy, arylalkoxy; A = halogen; m = 0-4; n = 0-3) and their thiourea analogs I (X = S) are prepd. and their use as factor VIIa inhibitors is disclosed. Thus, compd. II was prepd. by amidation of L-alanine Et ester with 4-aminobenzonitrile with subsequent hydrolysis, amidation, addn. of hydrogen sulfide, methylation and reaction with ammonia. I exhibited strong antithrombotic effects and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. Inhibition consts. of I towards factor VIIa/tissue factor ranged from 0.13-20.2 uM. I are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended.


IT 379259-63-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restenoses)

RN 379259-63-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT